Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

Background and aimCardiotoxicity has become the most common cause of non-cancer death among breast cancer patients. Pyrotinib, a tyrosine kinase inhibitor targeting HER2, has been successfully used to treat breast cancer patients but has also resulted in less well-understood cardiotoxicity. This pro...

Full description

Bibliographic Details
Main Authors: Yezi Chai, Meng Jiang, Yaohui Wang, Qiming Liu, Qifan Lu, Zhengyu Tao, Qizhen Wu, Wenjin Yin, Jinsong Lu, Jun Pu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
pyrotinib
cardiotoxicity
HER2-positive breast cancer
therapy-related cardiac dysfunction
echocardiography
magnetic resonance
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1021937/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1021937/full

Similar Items